Trial Profile
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel
- Indications Cardiovascular disorders; Stroke; Thromboembolism
- Focus Pharmacodynamics
- Acronyms ADRIFT
- 04 Dec 2019 Status changed from active, no longer recruiting to completed.
- 29 Jul 2019 Planned End Date changed from 23 Apr 2019 to 30 Sep 2019.
- 17 Jan 2019 Planned End Date changed from 23 Dec 2018 to 23 Apr 2019.